A key step
PharmNovo AB have been granted a patent in the USA for our candidate delta opioid receptor agonist PN6047. The European Patent Office is very likely to follow suit early in 2019. PN6047 is a biased delta opioid receptor agonist (DOBRA) favouring signalling through G proteins and, in preclinical testing, it has none of the unwanted side effects of conventional opioid analgesics. PharmNovo AB have been granted a patent in the USA for our candidate delta opioid receptor agonist PN6047. This is a key step towards clinical testing for the treatment of chronic pain states.
The European Patent Office is very likely to follow suit early in 2019. PN6047 is a biased delta opioid receptor agonist (DOBRA) favouring signalling through G proteins and, in preclinical testing, it has none of the unwanted side effects of conventional opioid analgesics.
A key step
PharmNovo AB have been granted a patent in the USA for our candidate delta opioid receptor agonist PN6047. The European Patent Office is very likely to follow suit early in 2019. PN6047 is a biased delta opioid receptor agonist (DOBRA) favouring signalling through G proteins and, in preclinical testing, it has none of the unwanted side effects of conventional opioid analgesics. PharmNovo AB have been granted a patent in the USA for our candidate delta opioid receptor agonist PN6047. This is a key step towards clinical testing for the treatment of chronic pain states.
The European Patent Office is very likely to follow suit early in 2019. PN6047 is a biased delta opioid receptor agonist (DOBRA) favouring signalling through G proteins and, in preclinical testing, it has none of the unwanted side effects of conventional opioid analgesics.
Latest news
View all
Watch PharmNovo at LSX in Lisbon
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read more
Capsules ready for Phase IIa Study
PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read more
Welcome on Board
As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Read more
